New drug combo targets tough lung cancer in early trial

NCT ID NCT04227028

Ongoing Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated Jun 10, 2026 · Updated 35 times

Summary

This early-phase study tests a combination of two drugs, brigatinib and bevacizumab, in people with a specific type of lung cancer (ALK-positive) that has spread or returned after prior ALK-directed therapy. The main goals are to find the best dose and check for side effects. Only 5 participants are enrolled, so results are very preliminary.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

City of Hope Medical Center

Duarte, California, 91010, United States
Northwestern University

Chicago, Illinois, 60611, United States
Penn State Cancer Institute

Hershey, Pennsylvania, 17033, United States
Rush University Medical Center

Chicago, Illinois, 60612, United States
University of Colorado Cancer Center

Aurora, Colorado, 80045, United States
University of Wisconsin Hospital and Clinics

Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.